Augurex Life Sciences Corp., a key player in the establishment of autoimmune-related diagnostics, have introduced its upcoming 14-3-3eta test to soon ramp the official stage. The 14-3-3eta test is approved as JOINTstat® in the UK and Canada and came into recognition via Sonic Reference Laboratory, a USA-based division of Sonic Healthcare. Starting from 15th December 2025, the test will be accessible to healthcare providers throughout the United States and join Sonic’s diagnostic portfolio.
The 14-3-3eta test improves the management and early detection of rheumatoid arthritis (RA). This helps clinicians by providing a robust tool to improve care and refine outcomes. This test is a clinically evident test and a qualified prognostic and diagnostic test. It also monitors blood-related biomarkers for RA, along with the accelerated levels linked with the disease severity, onset, progression and elevated risk of joint unfavorable events.
The test is specifically a valuable one to address patients getting the benefit of improvement from early intervention, and also for the patient population with seronegative RA. Its multiple roles in serving as ongoing monitoring and diagnosis make this test a comprehensive tool for refining long-standing outcomes and for conveying therapeutic decisions in the RA patient group.
CEO of Augurex, Neil Klompas, said, “Introducing 14-3-3eta with Sonic Healthcare USA and Sonic Reference Laboratory is a crucial decision, opening ways and space to access this essential test for patients and clinicians throughout the US. Sonic’s dedication and national recognition for diagnostic excellence are entangled with their deep worldwide experience in laboratory sciences. This makes them a perfect partner to contribute to our mission of enhancing the outcomes for the patient population suffering from autoimmune diseases.”
The Sonic Reference Laboratory stands on the latest 14-3-3eta test commercialisation by various key laboratories. The laboratories that hold the rapid momentum cycle for biomarker-related diagnostics in RA. Sonic Healthcare USA, a division of Sonic Healthcare Limited, is a part of the world’s popular and huge medical diagnostics companies, serving laboratory services throughout eight countries and providing care to more than 100 million patients a year.
It’s keen eye on quality and innovation complements and suits Augurex’s dedication to upgrading clinical tools that enhance patient care in North America and globally as well. This launch of a new test will accelerate growth and development in the vast global healthcare sector.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
